LEVOFLOX is a fluoroquinolone antibiotics indicated in the treatment of Acute bacterial sinusitis Acute exacerbations of chronic bronchitis Community-acquired pneumonia Complicated skin and soft tissue infections.
LEVOFLOX inhibits the enzyme bacterial DNA gyrase and prevents replication of bacterial DNA during bacterial growth and reproduction.
LEVOFLOX is rapidly and almost completely absorbed orally with peak plasma concentrations occurring within 1 to 2 hours. Bioavailability: approximately 99-100% It is stereo-chemically stable in plasma and urine and does not invert metabolically to its enantiomer, D-ofloxacin. Elimination half-life: 6 to 8 hours.
For Nosocomial Pneumonia 750 mg orally PO for 7 to 14 days Usual Adult Dose for Pneumonia Community acquired pneumonia Due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumonia, Haemophilus influenza, H. parainfluenzae, Klebsiella pneumonia, Moraxella catarrhalis, Chlamydophila pneumonia, legionella pneumophila or Mycoplasma pneumonia: 500 mg PO 7 to 14 days.
Available in 500/750mg tablet Each strip contains 10 tablets.